Evidence map›Paper›PMID 27118587›Full record

ArticlemBio2016

Peptidomimetic Small Molecules Disrupt Type IV Secretion System Activity in Diverse Bacterial Pathogens.

Carrie L Shaffer, James A D Good, Santosh Kumar, K Syam Krishnan, Jennifer A Gaddy, John T Loh, Joseph Chappell, Fredrik Almqvist, Timothy L Cover, Maria Hadjifrangiskou

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The extended mobility of plasmids.Nucleic acids research · 2025
    Review
  5. Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Carrie L ShafferDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
James A D GoodDepartment of Chemistry, Umeå University, Umeå, Sweden Umeå Centre for Microbial Research, Umeå University, Umeå, Sweden.
Santosh KumarDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA.
K Syam KrishnanDepartment of Chemistry, Umeå University, Umeå, Sweden.
Jennifer A GaddyDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
John T LohDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Joseph ChappellDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA.
Fredrik AlmqvistDepartment of Chemistry, Umeå University, Umeå, Sweden Umeå Centre for Microbial Research, Umeå University, Umeå, Sweden.
Timothy L CoverDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.ORCID http://orcid.org/0000-0001-8503-002X
Maria HadjifrangiskouDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA maria.hadjifrangiskou@vanderbilt.edu.
Vanderbilt University · USUmeå University · SEUniversity of Kentucky · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1986 to 2011
$28.1M
Role of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 2009 to 2026
$27.5M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
THREE-TIERED PREVENTION MODEL TO BETTER SERVE ALL STUDENP30HD015052 · NICHD · VANDERBILT UNIVERSITY · PI DYKENS, ELISABETH MAY · 1985 to 2014
$18.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Structure-function analysis of H. pylori VacAR01AI039657 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TIMOTHY L COVER · 1996 to 2026
$8.3M
Type IV Protein Secretion in Helicobacter pyloriR01AI118932 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COVER, TIMOTHY L, OHI, MELANIE DIANE · 2016 to 2025
$6.7M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
BLRD VA I01 BX000627BLRD VA IK2 BX001701NCATS NIH HHS UL1 TR000445NCI NIH HHS CA116087NCI NIH HHS CA68485NCI NIH HHS P01 CA116087NCI NIH HHS P30 CA068485NEI NIH HHS EY08126NEI NIH HHS P30 EY008126NIAID NIH HHS AI039657NIAID NIH HHS AI118932NIAID NIH HHS R01 AI039657NIAID NIH HHS R01 AI118932NICHD NIH HHS HD15052NICHD NIH HHS P30 HD015052NIDDK NIH HHS DK20593NIDDK NIH HHS DK58404NIDDK NIH HHS DK59637NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P60 DK020593NIDDK NIH HHS U24 DK059637PHS HHS 5 T32 A1007474-19PHS HHS T32 A1007474-19
6 · The paper itself

Abstract

unlabelledBacteria utilize complex type IV secretion systems (T4SSs) to translocate diverse effector proteins or DNA into target cells. Despite the importance of T4SSs in bacterial pathogenesis, the mechanism by which these translocation machineries deliver cargo across the bacterial envelope remains poorly understood, and very few studies have investigated the use of synthetic molecules to disrupt T4SS-mediated transport. Here, we describe two synthetic small molecules (C10 and KSK85) that disrupt T4SS-dependent processes in multiple bacterial pathogens. Helicobacter pylori exploits a pilus appendage associated with the cag T4SS to inject an oncogenic effector protein (CagA) and peptidoglycan into gastric epithelial cells. In H. pylori, KSK85 impedes biogenesis of the pilus appendage associated with the cag T4SS, while C10 disrupts cag T4SS activity without perturbing pilus assembly. In addition to the effects in H. pylori, we demonstrate that these compounds disrupt interbacterial DNA transfer by conjugative T4SSs in Escherichia coli and impede vir T4SS-mediated DNA delivery by Agrobacterium tumefaciens in a plant model of infection. Of note, C10 effectively disarmed dissemination of a derepressed IncF plasmid into a recipient bacterial population, thus demonstrating the potential of these compounds in mitigating the spread of antibiotic resistance determinants driven by conjugation. To our knowledge, this study is the first report of synthetic small molecules that impair delivery of both effector protein and DNA cargos by diverse T4SSs. IMPORTANCE: Many human and plant pathogens utilize complex nanomachines called type IV secretion systems (T4SSs) to transport proteins and DNA to target cells. In addition to delivery of harmful effector proteins into target cells, T4SSs can disseminate genetic determinants that confer antibiotic resistance among bacterial populations. In this study, we sought to identify compounds that disrupt T4SS-mediated processes. Using the human gastric pathogen H. pylori as a model system, we identified and characterized two small molecules that prevent transfer of an oncogenic effector protein to host cells. We discovered that these small molecules also prevented the spread of antibiotic resistance plasmids in E. coli populations and diminished the transfer of tumor-inducing DNA from the plant pathogen A. tumefaciens to target cells. Thus, these compounds are versatile molecular tools that can be used to study and disarm these important bacterial machines.

Indexed as

Agrobacterium tumefaciensBacterial ProteinsEscherichia coliHelicobacter InfectionsHelicobacter pyloriHumansPeptidomimeticsPlant DiseasesProtein TransportSmall Molecule LibrariesType IV Secretion SystemsBacterial ProteinsPeptidomimeticsSmall Molecule LibrariesType IV Secretion Systems

Identifiers

PMID27118587
PMCPMC4850256
OpenAlexW2342570290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.